American Society of Interventional Pain Physicians | December 20, 2017

The American Society of Interventional Pain Physicians will hold its 20th Annual Meeting March 15-17, 2018 in Orlando, Florida at Marriott Orlando World Center.

March 15, 2018

Raj-Racz Distinguished Lecture Series
  • Mesenchymal Stem Cells: Today, Tomorrow, and Future of Pain Management: Arnold Caplan, PhD
  • Evidence Synthesis in IPM: Evolution of EBM or Death of Expertise and Truth: Laxmaiah Manchikanti, MD

Best Practices in Pain Management in the Context of Addressing the National Opioid Epidemic
  • Current State of Opioid Epidemic: Laxmaiah Manchikanti, MD
  • Turning the Tide on the Opioid Tsunami Crisis: Understanding Pain, Policy, Opioids and Solutions: Anita Gupta, DO, PharmD
  • Addressing National Opioid Epidemic: Jerome Adams, MD, Surgeon General
  • The Opioid Crisis and Pain Management: Vanila Singh, MD

Moderator: Peter Staats, MD, Laxmaiah Manchikanti, MD, Anita Gupta, MD, PharmD, Vanila Singh, MD
Jerome Adams, MD, Surgeon General

  • Resident/Fellow Section
  • Regenerative Medicine
  • Emerging Concepts in Interventional Pain Management
  • Society of Interventional Pain Management Surgery Centers
  • Abstract session
  • Endoscopic Lumbar Decompression
  • Current Concepts in IPM
  • Neuromodulation

March 16, 2018

Manchikanti Distinguished Lecture Series
  • State of Health Care in the US: Past, Present, and Future: Robert Laszewski
  • Health Care Advocacy: ASIPP Involvement with Grass Roots Advocacy: Ed Whitfield
  • Health Care Reform: A View from Washington: Tim Hutchinson

Moderator: Joshua Hirsch, MD
Robert Laszewski, Ed Whitfield, Tim Hutchinson, Laxmaiah Manchikanti, MD, Amol Soin, MD

Best Practices in IPM
  • Advances in Neuromodulation: Ricardo Vallejo, MD
  • Shared Research and Entrepreneurship for Preservation of Interventional Pain Management: Amol Soin, MD
  • Evolution of ASIPP: Hans Hansen, MD
  • What Can Members Do to Preserve IPM: Citizenship: Dharam Mann, MD

  • Resident/Fellow Session
  • Compliance, Billing and Coding
  • Opioids
  • Emerging Concepts in IPM
  • Family Session
  • Managing Spinal Stenosis Beyond Epidurals: The Role of Interventionalist
  • Dry Needling
  • Imaging for Interventionalists
  • Research and Publications in Interventional Pain Management as Part of Your Practice

March 17, 2018

Senator Cassidy and other keynotes and 8 panel discussions on various subjects of interventional pain management until 5 pm.
ASIPP is Pleased to announce Dike Drummond, the Happy MD, as a Keynote Speaker at the Annual Meeting
Dike Drummond MD, CEO
Physician Coach and Healthcare Speaker

Dike Drummond MD is a Mayo trained Family Practice Physician and the leading coach, trainer and consultant on ...

  • The prevention of burnout in individual physicians
  • The realization of the Quadruple Aim in healthcare organizations

Dr. Drummond is a Mayo trained family doctor, professional coach, author, speaker and trainer whose sole professional focus since 2011 has been addressing the modern burnout epidemic in physicians.

He has two keynote speeches during the General Session on Saturday

8:30am – 10:00am               
Burnout Proof Live Workshop: Lower Stress Levels, Build More Life Balance and a More Ideal Practice with Practical Tools to Recognize and Prevent Burnout

1:00pm – 2:00pm               
The Quadruple Aim Blueprint: Four Steps to Proactive, Organization-Wide Burnout Prevention Program
Start Planning NOW!
ASIPP Abstract Submission for 2018 Annual Meeting is Open

This year, we will be making significant changes to the Abstract and Poster Sessions. Submissions will be in two categories: Resident/Fellow and Physician.  Selected posters will be on display for all meeting participants during all breaks and meal times.
The Abstract Committee will select the top 25 for publication in Pain Physician and of those 10 will be selected for Abstract presentation and judging during the Annual Meeting. The top 3 will receive cash prizes.

As Medical Care Shifts Out of Hospitals, Companies Plan Deals
A rapid-fire spate of deal-making among health-care companies in recent weeks is poised to accelerate the shift in how and where Americans get medical care—away from hospitals and toward clinics, doctors’ offices, surgery centers and even drugstores.
Potential mergers disclosed since early December involve companies with more than $550 billion in cumulative revenue, a sign of how large a swath of the industry is caught up in efforts to reshape the landscape. 
Tuesday,  Humana  Inc.  HUM -0.45%  and two private-equity firms  confirmed they plan  to acquire  Kindred Healthcare  Inc.  KND -4.74%  in a deal valued at around $810 million, or $4.1 billion including debt; they plan to split the health-care company in two, hiving off its long-term care and rehabilitation hospitals from its other business. The same day, Tenet Healthcare Corp. announced it is  exploring a sale of its health-care business-services arm , Conifer Health Solutions, amid pressure in its core hospital unit.
Access to this article may be limited.
Drug and Alcohol Deaths at U.S. Workplaces Soar
The number of U.S. deaths at work from unintentional drug and alcohol overdoses jumped more than 30% in 2016, according to new government data, showing that the nation’s struggle with a deadly opioid epidemic is migrating to the workplace.
The Bureau of Labor Statistics’ National Census of Fatal Occupational Injuries said Tuesday that  217 workers died on the job  last year as a result of an unintentional overdose from the nonmedical use of drugs or alcohol, up from 165 in 2015. The number of accidental overdose deaths at work has nearly tripled since the BLS began compiling the data in 2011.
The statistic is part of a bigger problem. Drug overdose deaths surpassed 64,000 last year, according to estimates by the Centers for Disease Control and Prevention. President Donald Trump in October declared opioid addiction, in particular, a national public health emergency.
Access to this article may be limited.

Interventional Pain Management Reports is an Open Access online journal, a peer-reviews journal dedicated to the publication of case reports, brief commentaries and reviews and letters to the editor. It is a peer-reviewed journal written by and directed to an audience of interventional pain physicians, clinicians and basic scientists with an interest in interventional pain management and pain medicine. 

Interventional Pain Management Reports is an official publication of the American Society of Interventional Pain Physicians (ASIPP) and is a sister publication of Pain Physician . Interventional Pain Management Reports Interventional Pain Management Reports is an open access journal, available online with free full manuscripts.  

The benefits of publishing in an open access journal that has a corresponding
print edition journal are:  
  • Your article will have the potential to obtain more citations.
  • Your article will be peer-reviewed and published faster than other journals.
  • Your article can be read by a potentially much larger audience compared with traditional subscription-only journals.  
  • Open Access journals are FREE to view, download and to print.

So submit today your:
  • Case Reports
  • Technical Reports
  • Editorials
  • Short Perspectives

Click HERE to submit
Challenges in Minimizing Post-Surgical Opioid Use
Gabapentin helped surgical patients stop opioid painkillers sooner in a placebo-controlled trial, although it didn't speed overall recovery from post-surgical pain, suggesting the drug could play a supporting role in combatting opioid overuse.
Meanwhile, a separate study added to the growing body of evidence that surgery patients are sent home with opioid prescriptions they may not need. In this research, nearly half of patients not needing opioids in the hospital got a prescription at discharge anyway.
Should HHS Negotiate Prescription Drug Prices?
WASHINGTON -- Experts shared their sometimes conflicting ideas for making prescription drugs more affordable during a hearing of the Senate Health, Education, Labor and Pensions (HELP) Committee Tuesday.
In his opening statement, HELP Chairman Lamar Alexander (R-Tenn.) described the variables that impact the cost of prescription drugs, such as a patient's choice of insurance plan, the availability of generic substitutes, and the net price following rebates and negotiations.
Many Physicians Have Experienced a Cyberattack in Practice
New research conducted by the American Medical Association (AMA) and Accenture highlights the seriousness of cyberattacks in healthcare and the need for more cybersecurity support to thwart these attacks.
Researchers surveyed 1,300 physicians in the US between July 2017 to August 2017 to examine experiences and attitudes toward cybersecurity, data management and compliance with the Health Insurance Portability and Accountability Act (HIPAA) guidelines.
Efficacy, Tolerability of Intranasal vs Intramuscular Naloxone for Opioid Overdose
According to the results of a recent systematic review published in the  Annals of Internal Medicine , 2 mg/mL intranasal naloxone may have comparable efficacy and tolerability to intramuscular naloxone. After overdose reversal, the benefits of transport to a hospital remain unclear.
Researchers evaluated cohort studies and randomized trials that compared  naloxone  dosing, administration routes, and transport to a hospital after opioid overdose. Mortality, reversal of overdose, recurrence of overdose, and harms were the main outcomes assessed.
Higher-concentration intranasal naloxone (2 mg/mL) was shown to have similar efficacy to intramuscular naloxone (2 mg) in one trial. In another trial, lower-concentration intranasal naloxone (2 mg/5 mL) was associated with lower effectiveness but reduced risk for agitation compared with intramuscular naloxone.
Vaping popular among teens; opioid misuse at historic lows
NIH’s 2017 Monitoring the Future survey shows both vaping and marijuana are more popular than traditional cigarettes or pain reliever misuse .
Nearly 1 in 3 students in 12 th  grade report past year use of some kind of vaping device, raising concerns about the impact on their health. What they say is in the device, however, ranges from nicotine, to marijuana, to “just flavoring.” The survey also suggests that use of hookahs and regular cigarettes is declining. These findings come from the 2017 Monitoring the Future (MTF) survey of eighth, 10th and 12th graders in schools nationwide, reported today by the director of the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, along with scientists from the University of Michigan, who conduct the annual research. The survey asks teens about “any vaping” to measure their use of electronic vaporizers. It is important to note that some research suggests that many teens do not actually know what is in the device they are using, and even if they read the label, not all labeling is consistent or accurate.
The survey shows that 27.8 percent of high school seniors reported “vaping” in the year prior to the survey, which was taken in the beginning of 2017. When asked what they thought was in the mist they inhaled the last time they used the vaping device, 51.8 percent of 12th graders said, “just flavoring,” 32.8 percent said “nicotine,” and 11.1 percent said “marijuana” or “hash oil.” The survey also asks about vaping with specific substances during the past month. Among 12 th  graders, more than 1 in 10 say they use nicotine, and about 1 in 20 report using marijuana in the device. 
FDA Takes Action Against Companies Selling Illicit Street Drug Alternatives
The Food and Drug Administration (FDA) is taking action against Arco Globus Trading, Legal Lean LLC and LegalLeanStore, the marketers and distributors of Legal Lean Syrup and Coco Loko. Both of these products may pose safety concerns as they are being promoted as alternatives to illicit street drugs.
Coco Loko is described as a snortable chocolate powder that contains taurine and guarana, neither of which have been evaluated for intranasal use. The FDA notes that snorting of the powder could lead to laryngospasm or bronchospasm and may induce or exacerbate asthma. 
An analysis of Legal Lean Syrup, which is labelled as a  dietary supplement , found that the product contains undeclared doxylamine, an antihistamine found in over-the-counter sleep aids and cough and cold medications. Unknown ingestion of doxylamine may pose a health risk to patients who have been advised to avoid the drug due to underlying medical conditions (ie, glaucoma, asthma, emphysema, chronic bronchitis, GI or GU obstruction).

Two Physician Groups Pay Over $33 Million to Resolve Claims Involving HMA Hospitals
  The Justice Department today announced settlements with two physician groups, EmCare Inc. (EmCare) and Physician’s Alliance Ltd (PAL), for allegedly receiving illegal remuneration in exchange for patient referrals to hospitals owned by the now-defunct Health Management Associates (HMA).
Dallas-based EmCare provides physicians to hospitals to staff their Emergency Departments (EDs). Under the settlement with EmCare, the physician group will pay $29.6 million to resolve allegations that, from 2008 through 2012, EmCare received remuneration from HMA to recommend patients be admitted to HMA hospitals on an inpatient basis when the patients should have been treated on an outpatient basis. On average, Medicare pays at least three times as much for an inpatient admission as it does for outpatient care. As part of the alleged scheme, HMA made certain bonus payments to EmCare ED physicians and tied EmCare’s retention of existing contracts and receipt of new contracts to increased admissions of patients who came to the ED. 
In a separate settlement, PAL, headquartered in Lancaster, Pennsylvania, and three of its executives, Lee Meyers, Michael Warren, M.D. and Wallace Longton, M.D., agreed to resolve allegations that, from 2009 until 2012, PAL accepted illegal remuneration from HMA to refer patients to two HMA hospitals, Lancaster Regional Medical Center and Heart of Lancaster Medical Center. Under the settlement, PAL and its executives will pay $4 million plus a percentage of proceeds from the sale of PAL’s interest in a joint venture with HMA.         
DaVita Rx Agrees to Pay $63.7 Million to Resolve False Claims Act Allegations
DaVita Rx LLC, a nationwide pharmacy that specializes in serving patients with severe kidney disease, agreed to pay a total of $63.7 million to resolve False Claims Act allegations relating to improper billing practices and unlawful financial inducements to federal healthcare program beneficiaries, the Justice Department announced today. DaVita Rx is based in Coppell, Texas.
The settlement resolves allegations that DaVita Rx billed federal healthcare programs for prescription medications that were never shipped, that were shipped but subsequently returned, and that did not comply with requirements for documentation of proof of delivery, refill requests, or patient consent. In addition, the settlement also resolves allegations that DaVita paid financial inducements to Federal healthcare program beneficiaries in violation of the Anti-Kickback Statute. Specifically, DaVita Rx allegedly accepted manufacturer copayment discount cards in lieu of collecting copayments from Medicare beneficiaries, routinely wrote off unpaid beneficiary debt, and extended discounts to beneficiaries who paid for their medications by credit card. These allegations relating to improper billing and unlawful financial inducements were the subject of self-disclosures by DaVita Rx and a subsequently filed whistleblower lawsuit.

State Society News 
April 18-22, 2018
GSIPP 2018 Annual Meeting
Georgia Society of Interventional Pain Physicians
Thursday, April 18, 2018 - Sunday, April 22, 2018
The Ritz Carlton Reynolds, Lake Oconee

July 19-22, 2018
FSIPP 2018 Annual Meeting, Conference, and Trade Show
Florida Society of Interventional Pain Physicians
One South County Road, Palm Beach, FL 33480

Send in your state society meeting news to Holly Long,
ASIPP | Pain Physician Journal | Phone | Fax | Email